Right2Breathe is a 501c3 patient advocacy organization dedicated to improving the lives of people living with lung diseases and providing free screenings to at risk populations. It is the Mission of Right2Breathe® to provide Education, Awareness, Free Screening, and Resources for people who are currently diagnosed or at higher risk of being diagnosed with respiratory disease. We believe that Everybody has a Right2Breathe. Right2Breathe was founded on the powerful idea that people can overcome difficult obstacles when they allow their passions in life to inspire them. The old adage, “When you do what you love, you don’t work a day in your life” applies to much more than just one’s career choices. We believe that the world is a better place when people use their gifts and talents to follow their dreams. Our mission is to inspire, educate, and empower people living with lung disease to rekindle the fire for their passions while providing the information necessary for them to take action. This will help them renew their commitment to their own wellness while inspiring other members of the respiratory patient community. In addition to the patient community, we provide education for caregivers who support them and the clinicians who treat people living with respiratory disease. We achieve our mission through Lung Health initiatives, multiple outreach and educational programs.
Pulmonary Fibrosis Foundation
The mission of the Pulmonary Fibrosis Foundation is to accelerate development of new treatments and ultimately a cure. We are committed to advancing improved care of PF patients and providing unequaled support and education resources. Through active engagement, the PFF has developed essential programs for those living and working with pulmonary fibrosis. We are proud to serve as the trusted resource for the pulmonary fibrosis community by raising awareness, providing disease education, and funding research.
Pulmonary Hypertension Association
Headquartered in Washington, D.C., the Pulmonary Hypertension Association is the oldest and largest nonprofit patient association dedicated to the pulmonary hypertension community. PHA’s mission is to extend and improve the lives of those affected by PH. Through support, advocacy and awareness, education, quality care and research programs, PHA empowers patients, caregivers, families, health care professionals and researchers worldwide. Our 2026 PHA International PH Conference and Scientific Sessions will take place on June 11-14, 2026 in Dallas.
Praxis Medical LLC
Praxis Medical is committed to developing innovative technologies that address unmet clinical needs to improve the lives of doctors, providers, and most importantly, patients. We are developing EndoCore- the world’s first motorized EBUS fine needle biopsy device. The EndoCore is designed to rotate the EBUS needle at the time of biopsy to harvest more cellular material in fewer passes. *This device is investigational.
PCD Foundation
The PCD Foundation is dedicated to improving the lives of individuals with primary ciliary dyskinesia (PCD) and to accelerating research to find a cure.
PAREXEL
Parexel is a leading global clinical development partner providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 22,000+ global employees work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ | Parexel is among the world’s largest CROs, providing full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, we collaborate with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials for patients. We work With HeartTM every day to treat patients with dignity and learn from their experiences, so every trial makes a difference.
NTM Info & Research
NTM Info & Research (NTMir) is a 501(c)(3) non-profit organization formed on behalf of patients with pulmonary nontuberculous mycobacterial (NTM) disease, bronchiectasis, and other related comorbid diseases for patient support, medical education, and research. NTMir’s mission is to save and improve lives by raising awareness, providing education and a broad support network for patients, and catalyzing research to promote early detection, accelerate the development of improved treatments and improve the quality of life for these patients.
Nordic Bioscience A/S
Nordic Bioscience is a Danish biomarker company headquartered in Herlev, Denmark. Nordic Bioscience is engaged in biomarker development using our unique neoepitope technology. We combine our expertise in biomarker development with preclinical and clinical research. This enables us to develop biomarkers that provide fast and objective decision-making for compound selection and development in clinical trials as well as provide value for patients in a diagnostic setting.
Nationwide Children’s Hospital
The Division of Pulmonary, Sleep Medicine and Cystic Fibrosis at Nationwide Children’s Hospital provides the highest quality clinical care for children and adults with congenital respiratory disorders, including cystic fibrosis, advanced lung disease, sleep-related breathing disorders and more. Our providers care for patients approaching and following lung/heart-lung transplant and those managing long-term mechanical ventilation. We are proud of the care we provide to children with respiratory disease, and this was acknowledged again this year by U.S. News & World Report as we have remained a top 10 pediatric pulmonary department since 2012! | At Nationwide Children’s Hospital, we understand the importance of translating innovative work beyond our walls and into the world. New technologies drive economic development in our local, national, and global ecosystem and most importantly, improve pediatric care. The Office of Technology Commercialization exists to ensure that the necessary partnerships are in place to execute this important function. Nationwide Children’s Hospital is one of America’s largest pediatric hospitals, an international leader in research, and is ranked in all 10 specialties on U.S. News & World Report’s 2023-24 “America’s Best Children’s Hospitals” list. In addition, according to the Children’s Hospital Association, Nationwide Children’s is the #1 provider of pediatric surgery in the country. The Abigail Wexner Research Institute at Nationwide Children’s Hospital has earned its reputation as an institution with a remarkable track record of moving discoveries into the marketplace. The hospital’s innovators, stationed in more than 800,000 square feet of dedicated research space, are committed to enhancing the health of children by engaging in high-quality, cutting-edge research according to the highest scientific and ethical standards while advancing life-saving therapies to children everywhere. The Office of Technology Commercialization at Nationwide Children’s guides ideas to solutions by offering expertise in technology transfer and facilitating partnerships between inventors and industry to bring discoveries to patients, clinicians and scientists around the world. Our resourceful team guides Nationwide Children’s clinicians, researchers, and partners through complex processes with creative solutions. This ranges from therapeutics, biomarkers, diagnostic tools, research and clinical tools, and medical devices. Some of our successes include first-of-their-kind gene therapies, Zolgensma and Elevidys – FDA-approved treatments for Spinal Muscular Atrophy (SMA) and Duchenne Muscular Dystrophy (DMD) – and medical devices like the Comfort Collar or the Endoscopic Retrieval Device. Nationwide Children’s Hospital, located in Columbus, Ohio and with over 16,000 employees, is leading a bold journey to best outcomes for children everywhere. | The Nationwide Children’s Hospital Office of Technology Commercialization (OTC) guides ideas to solutions by offering expertise in technology transfer and facilitating partnerships between inventors and industry to bring discoveries to patients, clinicians and scientists around the world. Our resourceful team guides inventors and partners through complex processes with creative solutions. This ranges from therapeutics, including the approved, first-of-their-kind gene therapies – Zolgensma and Elevidys, FDA-approved treatments for Spinal Muscular Atrophy (SMA) and Duchenne Muscular Dystrophy (DMD) – to biomarkers, diagnostic tools and clinical tools – such as the Comfort Collar, designed to prevent pressure wounds around tracheostomy tubes – to outside partners to benefit patients, the local community and the general public. As a result, the Abigail Wexner Research Institute at Nationwide Children’s Hospital has earned its reputation as an institution with a remarkable track record of moving discoveries into the marketplace. The hospital’s physicians and researchers are dedicated to enhancing the health of children by engaging in high-quality, cutting-edge research according to the highest scientific and ethical standards while advancing life-saving therapies to children everywhere. We encourage all interested entrepreneurs and potential licensing partners to stop by the Ohio Pavilion (Booth No. 1865) to discuss our many available preclinical and clinical technologies, ranging from early-stage innovations to market-ready products. Our portfolio of over 200 available technologies developed by our innovative researchers and clinicians at Nationwide Children’s Hospital is diverse and ever-growing. | The Office of Technology Commercialization (OTC) at Nationwide Children’s Hospital supports the translation of innovative research into real-world healthcare solutions. Working closely with clinicians, researchers, and industry partners, OTC advances intellectual property development, licensing, and startup formation to bring pediatric-focused technologies to market. OTC also collaborates closely with the Nationwide Children’s Innovation Center to foster cross-disciplinary innovation and accelerate the development of novel solutions from concept through commercialization. Nationwide Children’s Hospital is consistently ranked among the top 10 children’s hospitals in the nation by U.S. News & World Report, earning the “Honor Roll” distinction for 12 consecutive years as of 2025. It is also the #1 ranked pediatric hospital in Ohio and the Midwest and is consistently among the top NIH-funded pediatric research institutions in the United States, reflecting its national leadership in biomedical discovery and translational science. Together, Nationwide Children’s, the OTC and Innovation Center drive collaboration and commercialization efforts that accelerate the development of life-changing therapies, devices, and diagnostics for children worldwide.